{
  "docId": "019de075-7539-774f-abd7-26734f481c17",
  "docSlug": "efb32a48c20b71d9dd70ea37e2f1bc4b",
  "documentTitle": "argenx SE | Investor Presentation Deck | 26 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 26,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "geographic_map",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 16,
  "notes": "The slide uses a map to visualize global reach, supplemented by two tables detailing approval dates for two different products.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7539-774f-abd7-26734f481c17/10",
  "deckHref": "/decks/019de075-7539-774f-abd7-26734f481c17",
  "deckJsonHref": "/decks/019de075-7539-774f-abd7-26734f481c17.json",
  "deckAnchorHref": "/decks/019de075-7539-774f-abd7-26734f481c17#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.6,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "965ddeac-036e-434d-b6b1-328de15ec54f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.637,
        "y": 0.55
      },
      "kind": "table",
      "text": "VYVGART Hytrulo Approvals: U.S. (JUNE 2023), JAPAN (BY Q1 2024 Pending), EUROPE (Q4 2023 Pending), CHINA (2024 Pending)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d5429da-3eba-448d-b8bd-abc1409bf37a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.33,
        "x": 0.637,
        "y": 0.15
      },
      "kind": "table",
      "text": "VYVGART Approvals: U.S. (DEC 2021), JAPAN (JAN 2022), EUROPE (SEPT 2022), UK (MAR 2023), ISRAEL (APRIL 2023), CHINA (JUNE 2023), CANADA (Q3 2023 Pending)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a2e1dbb-5b18-4d65-84f4-5f6cf509c7b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Reaching gMG Patients Across the Globe",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a96c339-f4d3-4bd9-8966-024bc9d10412",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "11df2160-3e69-4fb0-a01d-c12161d32bad",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What",
      "beatSlug": "golden-circle-what",
      "evidence": "Slides 6-10 describe VYVGART and its benefits for patients with Generalized Myasthenia Gravis.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5a9162d2-2912-4933-9e05-dd879960544e",
      "evidence": "The document emphasizes the complexity and burden of existing treatments.",
      "position": 0,
      "objective": "Highlighting the need for improved treatment options for autoimmunity patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}